CFM
MAIA icon

Catalyst Funds Management’s MAIA Biotechnology MAIA Stock Holding History

Catalyst Funds Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1K Buy
+10,800
New +$19.9K ﹤0.01% 579

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's MAIA Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in MAIA Biotechnology (MAIA) in Q1 2026: 10,800 shares worth $15.1K. The stake represents ﹤0.01% of the portfolio and ranks #579 among its holdings.

33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

  • Catalyst Funds Management held 10,800 shares of MAIA Biotechnology worth $15.1K as of Q1 2026.
  • MAIA Biotechnology was a new Catalyst Funds Management position in Q1 2026.
  • MAIA Biotechnology made up ﹤0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #579 holding.
  • 33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.